The relationship between modulation of MDR and glutathione in MRP-overexpressing human leukemia cells

被引:30
作者
Grech, KV
Davey, RA
Davey, MW
机构
[1] Univ Technol, Dept Cell & Mol Biol, Gore Hill, NSW 2065, Australia
[2] Royal N Shore Hosp, Bill Walsh Canc Res Labs, Dept Clin Oncol, St Leonards, NSW 2065, Australia
关键词
multidrug resistance; multidrug resistance-associated protein; P-glycoprotein; glutathione; verapamil; SDZ PSC 833;
D O I
10.1016/S0006-2952(97)00562-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multidrug resistance-associated protein (MRP) causes multidrug resistance (MDR) involving the anthracyclines and epipodophyllotoxins. Many studies show modulation of anthracycline levels and cytotoxicity in MRP overexpressing cells, but there is limited data on the modulation of etoposide levels and cytotoxicity in MRP-overexpressing or in P-glycoprotein-expressing cells. Etoposide accumulation was 50% reduced in both the CEM/E1000 MRP-overexpressing subline and the CEM/VLB100 P-glycoprotein-expressing subline compared to the parental CEM cells, correlating with similar resistance to etoposide (200-fold) of the two sublines. For the CEM/VLB100 subline, the P-glycoprotein inhibitor SDZ PSC 833, but not verapamil, was able to increase etoposide accumulation and cytotoxicity. For the CEM/E1000 subline, neither SDZ PSC 833 nor verapamil had any effect on etoposide accumulation. However, verapamil caused a 4-fold sensitization to etoposide in this subline, along with an 80% decrease in cellular glutathione (P < 0.05). Buthionine sulfoximine (BSO), which depletes glutathione, also caused a 2.5-fold sensitization to etoposide with no effect on accumulation in the CEM/E1000 subline. In contrast, SDZ PSC 833 was able to increase daunorubicin accumulation in the CEM/E1000 subline (P < 0.05), but had no effect on daunorubicin cytotoxicity, or cellular glutathione. These results show that modulation of etoposide cytotoxicity in MRP-overexpressing cells may be through changes in glutathione metabolism rather than changes in accumulation and confirm that changes in drug accumulation are not related to drug resistance in MRP-overexpressing cells. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:1283 / 1289
页数:7
相关论文
共 18 条
[1]  
BECK WT, 1979, CANCER RES, V39, P2070
[2]  
Curtin N., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P591
[3]   Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells [J].
Davey, MW ;
Hargrave, RM ;
Davey, RA .
LEUKEMIA RESEARCH, 1996, 20 (08) :657-664
[4]   DRUG-RESISTANCE MECHANISMS AND MRP EXPRESSION IN RESPONSE TO EPIRUBICIN TREATMENT IN A HUMAN LEUKEMIA-CELL LINE [J].
DAVEY, RA ;
LONGHURST, TJ ;
DAVEY, MW ;
BELOV, L ;
HARVIE, RM ;
HANCOX, D ;
WHEELER, H .
LEUKEMIA RESEARCH, 1995, 19 (04) :275-282
[5]   The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro [J].
Davey, RA ;
Su, GM ;
Hargrave, RM ;
Harvie, RM ;
Baguley, BC ;
Davey, MW .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (05) :424-430
[6]  
FOLEY GE, 1965, CANCER, V18, P156
[7]   Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells [J].
Ishikawa, T ;
Bao, JJ ;
Yamane, Y ;
Akimaru, K ;
Frindrich, K ;
Wright, CD ;
Kuo, MT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (25) :14981-14988
[8]  
Jedlitschky G, 1996, CANCER RES, V56, P988
[9]  
JEDLITSCHKY G, 1994, CANCER RES, V54, P4833
[10]  
Kane SE, 1996, ADV DRUG RES, V28, P181